Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Exclusive: Sanofi considers job cuts as CEO seeks to reduce costs - sources

Published 06/25/2020, 10:24 AM
Updated 06/25/2020, 12:40 PM
© Reuters. FILE PHOTO: Sanofi logo is seen in Paris
NOVN
-
SASY
-
GSK
-
HUD
-
TBIO_old
-
THOR
-

By Matthias Blamont

PARIS (Reuters) - Sanofi (PA:SASY) is considering cutting hundreds of jobs and will discuss potential steps with staff representatives over the coming days, five sources said on Thursday, the latest move by the French drugmaker's chief executive Paul Hudson (NYSE:HUD) to cut costs.

Management will meet staff representatives on Friday and Monday next week to outline a restructuring plan, five sources familiar with the matter told Reuters. They declined to be identified as the plan is still confidential.

The reorganisation could involve several European countries and possibly others outside the region, as well as all the divisions of Sanofi except the vaccines and rare diseases unit Genzyme, the sources said.

Three sources said around 1,000 jobs in France were at risk. One of the sources said the cuts would take place over a three-year period, with no forced redundancies.

Sanofi said strategy matters would be discussed at two meetings convened for June 26-29. "Information will be shared with staff representatives first and no redundancy plan will be presented then," the company said in an e-mailed statement.

The discussions come after Hudson announced in December plans to cut 2 billion euros ($2.24 billion) in costs by 2022. He joined the company in September from Novartis (S:NOVN).

"The COVID-19 (pandemic) had slowed the announcement, but (the measures) are part of the CEO roadmap," one of the sources said.

Hudson has pledged to commit resources in areas where he believes Sanofi can secure leading positions.

Since his arrival, the company ended research in diabetes and cardiovascular, an area where Sanofi had lost ground over the years, narrowed the number of its divisions and set out higher profit targets.

The group has also been bulking up, including in the lucrative field of cancer drugs. It announced a deal last year to buy U.S. biotechnology firm Synthorx (O:THOR) for about $2.5 billion.

Vaccines are also a top priority and the company is currently working on two candidates to prevent COVID-19, the illness caused by the new coronavirus that has killed more than 483,000 globally, one in partnership with GlaxoSmithKline (L:GSK) and another with U.S. Translate Bio (O:TBIO).

Sanofi said on June 16 it would invest 610 million euros at two French sites to turn them into a hub dedicated to research, development and production of vaccines, with some 200 new jobs expected to be created on one of the locations.

© Reuters. FILE PHOTO: Paul Hudson, CEO of Sanofi, delivers a speech at the French drugmaker's vaccine unit Sanofi Pasteur plant near Lyon

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.